| Literature DB >> 11041572 |
V S Tanphaichitr1, V Suvatte, S Issaragrisil, C Mahasandana, G Veerakul, V Chongkolwatana, W Waiyawuth, H Ideguchi.
Abstract
We report the first successful use of BMT for the treatment of RBC pyruvate kinase (PK) deficiency in a boy who developed neonatal jaundice and severe transfusion-dependent hemolytic anemia a few months after birth. He received a BMT at the age of 5 from an HLA-identical sister who has normal PK activity after conditioning with busulfan and cyclophosphamide. The post-transplant course was uneventful. At present, 3 years after transplant, he is 8 years old and has a normal hemoglobin level and normal RBC PK activity without evidence of hemolysis. DNA analysis has confirmed full engraftment.Entities:
Mesh:
Substances:
Year: 2000 PMID: 11041572 DOI: 10.1038/sj.bmt.1702576
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483